XUE, KAI
Effects of Recombinant Human Erythropoietin on Inflammatory Factors in Rats with Traumatic Brain Injury - Vol.83(3), May-June - Mumbai Indian Journal of Pharmaceutical Science 2021 - 541-546p.
To study the effects of recombinant human erythropoietin on inflammatory factors in rats with traumatic
brain injury is the main objective. A total of 45 specific-pathogen-free grade male Sprague-Dawley rats
were randomly assigned into sham operation group (sham group), model group and recombinant human
erythropoietin intervention group (treatment group) (n=15). Model and treatment groups were prepared
into traumatic brain injury model by hitting the head through the modified Feeney’s free-fall impact
method, while the head of sham group was not hit. After modeling, treatment group was intraperitoneally
injected with recombinant human erythropoietin at 5000 IU/kg daily and sham and model groups were
intraperitoneally injected with the same dose of normal saline. The rats were killed after 7 d of continuous
administration. The changes of brain mitochondrial membrane potential were detected through rhodamine
123 staining and immunocytochemistry and Western blotting were separately employed to measure the
expressions of interleukin-1β, interleukin-6 and tumor necrosis factor-α in brain tissues and the expression
levels of dynamin-related protein 1, fission 1, mitofusin 2 and optic atrophy 1, mitochondrial dynamics
related proteins in brain tissues. Compared with sham group, model group exhibited significantly weakened
rhodamine 123 fluorescence intensity, increased expressions of interleukin-1β, interleukin-6 and tumor
necrosis factor-α, dynamin-related protein 1 and fission 1 and reduced expressions of mitofusin 2 and optic
atrophy 1 in brain tissues (p<0.05). In comparison with model group, treatment group had significantly
enhanced rhodamine 123 fluorescence intensity, reduced expressions of interleukin-1β, interleukin-6 and
tumor necrosis factor-α, dynamin-related protein 1 and fission 1 and elevated expressions of mitofusin 2
and optic atrophy 1 in brain tissues (p<0.05). Recombinant human erythropoietin can protect the brain
after traumatic brain injury by relieving the inflammatory response and mitochondrial injury after
traumatic brain injury.
PHARMACEUTICS
Effects of Recombinant Human Erythropoietin on Inflammatory Factors in Rats with Traumatic Brain Injury - Vol.83(3), May-June - Mumbai Indian Journal of Pharmaceutical Science 2021 - 541-546p.
To study the effects of recombinant human erythropoietin on inflammatory factors in rats with traumatic
brain injury is the main objective. A total of 45 specific-pathogen-free grade male Sprague-Dawley rats
were randomly assigned into sham operation group (sham group), model group and recombinant human
erythropoietin intervention group (treatment group) (n=15). Model and treatment groups were prepared
into traumatic brain injury model by hitting the head through the modified Feeney’s free-fall impact
method, while the head of sham group was not hit. After modeling, treatment group was intraperitoneally
injected with recombinant human erythropoietin at 5000 IU/kg daily and sham and model groups were
intraperitoneally injected with the same dose of normal saline. The rats were killed after 7 d of continuous
administration. The changes of brain mitochondrial membrane potential were detected through rhodamine
123 staining and immunocytochemistry and Western blotting were separately employed to measure the
expressions of interleukin-1β, interleukin-6 and tumor necrosis factor-α in brain tissues and the expression
levels of dynamin-related protein 1, fission 1, mitofusin 2 and optic atrophy 1, mitochondrial dynamics
related proteins in brain tissues. Compared with sham group, model group exhibited significantly weakened
rhodamine 123 fluorescence intensity, increased expressions of interleukin-1β, interleukin-6 and tumor
necrosis factor-α, dynamin-related protein 1 and fission 1 and reduced expressions of mitofusin 2 and optic
atrophy 1 in brain tissues (p<0.05). In comparison with model group, treatment group had significantly
enhanced rhodamine 123 fluorescence intensity, reduced expressions of interleukin-1β, interleukin-6 and
tumor necrosis factor-α, dynamin-related protein 1 and fission 1 and elevated expressions of mitofusin 2
and optic atrophy 1 in brain tissues (p<0.05). Recombinant human erythropoietin can protect the brain
after traumatic brain injury by relieving the inflammatory response and mitochondrial injury after
traumatic brain injury.
PHARMACEUTICS